News
GTBP
3.107
-7.11%
-0.238
Weekly Report: what happened at GTBP last week (0422-0426)?
Weekly Report · 21h ago
Weekly Report: what happened at GTBP last week (0415-0419)?
Weekly Report · 04/22 12:28
Weekly Report: what happened at GTBP last week (0408-0412)?
Weekly Report · 04/15 12:18
Weekly Report: what happened at GTBP last week (0401-0405)?
Weekly Report · 04/08 12:23
Weekly Report: what happened at GTBP last week (0325-0329)?
Weekly Report · 04/01 12:20
GT Biopharma Inc reports results for the quarter ended in December - Earnings Summary
GT Biopharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.19 per share. Reported revenue was zero; analysts expected zero. Shares had fallen by 42.9% this quarter. The average analyst rating on the shares is "buy"
Reuters · 03/28 12:00
GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023
GT Biopharma reported earnings per share of -$2.14. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of - $2.70. The stock was down 2.7% after the market closed.
Investorplace · 03/27 01:53
GT Biopharma reports Q4 results
GT Biopharma, Inc. Reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023. The company had cash, cash equivalents and short-term investments of $13.97 million at the end of the quarter. GT Biopharm reports Q4 results.
Seeking Alpha · 03/26 21:17
Recap: GT Biopharma Q4 Earnings
GT Biopharma reported its Q4 earnings results on March 26. The company beat estimates by 21.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $1.2 and the company's share price rose 8.0% after the announcement.
Benzinga · 03/26 21:15
GT Biopharma Q4 EPS $(2.14) Beats $(2.70) Estimate
Benzinga · 03/26 21:14
*GT Biopharma 4Q R&D Expenses $1.4M >GTBP
Dow Jones · 03/26 21:02
*GT Biopharma: Cash Runway to Fund Ops Into 2025 >GTBP
Dow Jones · 03/26 21:02
*GT Biopharma 4Q Loss $3M >GTBP
Dow Jones · 03/26 21:02
GT Biopharma Inc <GTBP.OQ> expected to post a loss of $2.70 a share - Earnings Preview
GT Biopharma Inc expected to post a loss of $2.70 a share - Earnings Preview. The one available analyst rating on the shares is "buy" The company is expected to show change in quarterly revenue when it reports results on March 28.
Reuters · 03/26 11:02
Weekly Report: what happened at GTBP last week (0318-0322)?
Weekly Report · 03/25 12:23
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. Fell sharply on Friday after the company reported worse-than-expected fourth quarter adjusted EPS results. Murano Global Investments PLC shares jumped 147.5% to $23.94 after falling 46% on Thursday. Other stocks moving in today's mid-day session include Nova LifeStyle, Inc., Worthington Steel and Foot Locker.
Benzinga · 03/22 18:39
VERI, AMTX and ATNF among mid-day movers
On the Move VERI, AMTX and ATNF among mid-day movers. IMAC Holdings (BACK) and Nova Lifestyle (NVFY) Gainers: IMAC and Canopy Growth Corporation. Losers: Cannasoft Enterprises and Cutera.
Seeking Alpha · 03/22 17:02
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers
Healthcare On the Move: Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers. S&P 500 Health Care Sector +0.23% to 1703.09. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/22 14:00
Weekly Report: what happened at GTBP last week (0311-0315)?
Weekly Report · 03/18 12:21
Weekly Report: what happened at GTBP last week (0304-0308)?
Weekly Report · 03/11 12:16
More
Webull provides a variety of real-time GTBP stock news. You can receive the latest news about Gt Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.